George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
gggg21, @ 18:40 & Wilson63, this caught my eye also . .
Procurement Policy Note – Taking account
of a bidder’s approach to payment in the
procurement of major contracts
Action Note PPN 08/21 OCTOBER 2021
Issue
1. The Government understands the importance of prompt, fair and effective payment in all businesses. Being paid promptly for work done ensures . . etc.
Dissemination and Scope
3. For the avoidance of doubt, this PPN does not apply to NHS trusts or to contracting authorities whose functions are devolved or mainly devolved functions of Scotland, Wales or Northern Ireland.
Nice joke Wilson thanks lol
Gggg21 I've not read fully yet but this immediately caught my eye
ue
1. The Government understands the importance of prompt, fair and effective payment in all businesses. Being paid promptly for work done ensures businesses have a healthy cash flow. This Procurement Policy Note (PPN) sets out how payment approaches can be taken into account in the procurement of major Government contracts.
Classic.
until the dispute is settled then larger order done, or promate given as part of dispute resolution....
https://www.gov.uk/government/publications/procurement-policy-note-0821
This caught my interest with the £5m amount, maybe coincidence that the last promate order was just below the £5m threshold...could it have been on purpose, will orders be in sub £5m blocks....
Reading PI100's message at 7:50 would likely lead potential new investors to believe that we have no presence at all in LFT.
It's always good to address the rather negative posts with a reminder that ncyt are very much in the LFT market as well as the PCR market, as well as the antibody market, as well as the variant market. So there is a clear link that the more cases increase the more revenue ncyt will be generating.
Whether that is reflected in the SP immediately is another thing entirely.
MonkeyFish yes agree fully, seems to be a bureaucratic nightmare and shows just how much competition there is.
With LFTs literally anyone can start a company, license a test from China and sell it under their own brand. There are already several such cases in the UK where for example Hughes Healthcare licensed the Acon LFT under their own brand.
This is no different to Novacyts plan I believe (for the Antigen test) but it means that the approval system is super clogged up as each sub brand needs to go through their own approval process
But as you say also, means that the whole LFT thing is probably not a high earner at all. Novacyts edge would be their existing client base and distribution network but margins would still be zero. Thats why I laugh when I see people of twitter on the ODX hashtag bashing Novacyt that "PCR is dead" when in fact PCR is what is making money!
A lot of the Omega investors assumption seems to be that production capacity = sales as they will "sell out due to demand".
With so many tests being imported I struggle to see this as feasible, even for Novacyt, unless they are the cheapest.
End consumers will only care about one single thing - price. As such distributors will only care about one single thing - price. So the only manufacturers that will max out their volume are the cheapest, selling at the lowest margins.
So long story short, I don't think LFTs will be making any headline profit numbers for anyone not even Novacyt. I think for Novacyt it's more about proving their capabilities and selling it as an all in one package to clients (sweeten the big PCR deals with some free cheap LFTs)
Don't know about the sp but trade fair attendance is certainly on the up
Yet another trade show in the diary for
@NovacytGroup
Aidex in Brussels
So far:
AACC - Atlanta - 28 to 30 Sept
ASHG - Virtual - 18 to 22 Oct
Lab Innovations - B'ham - 3 to 4 Nov
Compamed - Düsseldorf - 15 to 18 Nov
AidEx - Brussels - 17 to 18 Nov
Tks to blackbird investing full post
https://twitter.com/BlackbirdInvest/status/1451114427319791619
@InvestorSteve
I don’t really understand why there is such a delay for home self test v the professional test already having been approved. A number of U.K. LFT manufacturers are also facing a delay, so not just a Novacyt issue. Having watched a nurse go through the process of testing me abroad, it was no different to doing it myself. As long as you follow the instructions properly, which I appreciate some won’t, I really don’t understand the difference. I appreciate the volume of approvals can create pressure for the approval body, but I can’t believe that they couldn’t haven’t accelerated this process if they had wanted to. They managed to get the PCR tests validated recently. The LFT margin is going to be tight given the price points of the competition from the Far East, who already provide some of the LFTs that you can buy for self certification to fly home from abroad, so I don’t think that this is going to be a material profit stream for us. The announced delay was just a reason to bash the SP, despite £100m rev for the year excluding DHSC and any material sales from home use LFTs, being confirmed again and again.
The antibody test is more interesting, but looking at the daily numbers from the Gov website there are fewer than 5k a day tests over the past week, so what will the demand be?
The LFT antigen Pro and the basic non differentiating LFT antibody have both been out for some time....the real issue is PRICE and no company (all non far east) will ever going to compete with the far east and LFT self test kits....that's why IMO, NCYT have gone for near to patient testing POC with PCR and master mixes/ PROmate/ non COVID etc....that's where the money is and will be for the longest time.....mind you, I do see vaccine makers needing an easy differentiating LFT antibody
imo novacyt (microgen) have the manufacturing capacity to make whatever lft they want in reality at scale, they could white label, be competitive, have all the accreditations/iso etc and distribution network, based in england (remember only england is lft for travel in UK). So if we want to add this revenue stream then easy reseller agreement.
DRB83 there are two delayed LFTs:
1) The antibody one which would distinguish between Vaccine and Infection Antibodies
2) The Self test version of out Antigen test
The professional version of the Antigen test is alive and kicking
Pi, is it both our LFT s that are delayed?
No BB I don't think it will be that simple this time around, we need our own positive news and updates on top of the wider outlook -but it will come.
The positive bit is that despite the total lack of interest this doesn't seem to go below 250p so expect more consolidation at least before the next breakout.
It’s been headlines pretty much every day this year and we’re red almost every day. What link have you made with ncyt? Nee LFT delayed 6 months until after winter and pcr hardly got a good rep at the moment, not to mention our biggest hope is DHSC who renege on their contracts and don’t pay.. so, how is this going to push us up?
No but coronavirus increases was on the front pages of all news yesterday
Have we released news then? Can’t see an RNS.
Covid ballooning. I’m back in. Could get v interesting this winter here at NCYT